PTC Therapeutics, CHMP and Translarna
PTC Therapeutics: CHMP Again Recommends Against Translarna Renewal
PTC Therapeutics has suffered another setback in its bid to keep its Duchenne muscular dystrophy drug Translarna on the market in Europe. PTC on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use has once again recommended against renewal of the conditional marketing authorization for Translarna.
Barchart on MSN9h
PTC’s Q4 2024 Earnings: What to ExpectValued at a market cap of $22.1 billion, PTC Inc. (PTC) provides software solutions and services that aid manufacturing ...
We recently compiled a list of the 10 Best 3D Printing Stocks To Buy Right Now. In this article, we are going to take a look ...
PTC Inc. is developing a strong annual recurring revenue model through its SaaS transition. Click here to find out why PTC ...
Several months after forging a fresh path forward for its troubled Friedreich ataxia (FA) drug vatiquinone, PTC Therapeutics ...
One of the tech industry’s biggest hype men, Salesforce CEO Marc Benioff, wants you to know that he is psyched about ...
The European Medicines Agency’s human medicines committee again decided not to recommend the renewal of the conditional ...
PTC ...
After hitting a wall with the FDA last year, Novo Nordisk has picked up backing from European drug reviewers for its novel ...
Stay in the know about climate impacts and solutions. Subscribe to our newsletters.
GameRant on MSN9d
New Meta Quest Feature Could Make Using Keyboards Much EasierA Meta Quest feature being tested could make using any keyboard while wearing the VR headset significantly easier for its ...
Without effective thermal protection, it would not be possible to use our household appliances safely. Because wherever ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback